|
|
|
Ibrutinib (9)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), first-line, combination with venetoclax
|
3,190–3,200
|
100%
additional benefit not proven
|
|
|
|
Ibrutinib (8)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), first-line, combination with rituximab
|
3,090
|
59%
Hint for
considerable additional benefit
Orphan (turnover limit)
|
|
|
|
Ibrutinib (6)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Chronische lymphatische Leukämie (CLL), Erstlinie, Kombination mit Obinutuzumab
|
3,090
|
26%
Hint for
minor additional benefit
Orphan (turnover limit)
|
|
|
|
Ibrutinib (7)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Waldenström's disease, combination with rituximab
|
590–1,180
|
100%
additional benefit not proven
Orphan (turnover limit)
|
|
|
|
Ibrutinib (5)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Chronic lymphocytic leukaemia (CLL), at least 1 prior therapy, combination with bendamustine and rituximab
|
1,500–5,600
|
50%
Hint for
considerable additional benefit
Orphan (turnover limit)
|
|
|
|
Ibrutinib (4)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Chronic lymphocytic leukemia (CLL), first-line
|
2,840
|
100%
additional benefit not proven
Orphan (turnover limit)
|
|
|
|
Ibrutinib (3)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL), Waldenström's disease
|
3,780–11,100
|
12%
Indication of
considerable additional benefit
Orphan (turnover limit)
|
|
|
|
Ibrutinib (2)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Waldenström's disease
|
n.d.
|
discontinued
Orphan
|
|
|
|
Ibrutinib (1)
|
Imbruvica®
|
Janssen-Cilag GmbH
|
Oncological diseases
|
Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL)
|
0
2,900–8,750
|
100%
non-quantifiable additional benefit
Orphan
repealed
|
